StockData
Corcept Therapeutics Inc logo

Corcept Therapeutics Inc (CORT) stock

CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026Score 11/30408% above fair value
$81.12−4.83 (-5.62%)

Close on Oct 30, 2026Market cap $8.77BP/E 193.1Yield –

Earnings

Corcept Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 3, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$256.10M
+31.7% on a year earlier
Adjusted EPS, Q2 FY2026
$0.36
$0.29 a year earlier
Latest guidance
Raised
Jul 29, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Corcept Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 3, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Jul 29, 2026after the close$256.10M+31.7%$0.36–Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026after the close$164.90M+4.9%-$0.30–Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026after the close$202.10M+11.1%$0.20–Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025after the close$207.60M+13.8%$0.16–Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025after the close$194.40M+18.7%$0.29–Release
Q1 FY2025ended Mar 31, 2025May 5, 2025after the close$157.20M+7.1%$0.17–Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025after the close$181.90M+34.3%$0.26–Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024after the close$182.50M+47.7%$0.41–Release
Q2 FY2024ended Jun 30, 2024Jul 29, 2024after the close$163.80M+39.2%$0.32–Release
Q1 FY2024ended Mar 31, 2024May 1, 2024after the close$146.80M+38.9%$0.25–Release
Q4 FY2023ended Dec 31, 2023Feb 15, 2024after the close$135.40M+31.3%$0.28–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Corcept Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenue guidanceFY2026$1.10B – $1.20B$950.00M – $1.05BRaisedJul 29, 2026

Guidance vs results

The last range Corcept Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$800.00M – $850.00M$761.30MΣ4QBelow range

Guidance history

Every forecast Corcept Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Jul 29, 2026revenue guidanceFY2026$1.10B – $1.20BRaised
Apr 30, 2026revenue guidanceFY2026$950.00M – $1.05BRaised
Feb 24, 2026revenue guidanceFY2026$900.00M – $1.00BNew
Nov 4, 2025revenue guidanceFY2025$800.00M – $850.00MNew
Jul 31, 2025revenue guidanceFY2025$850.00M – $900.00MLowered
May 5, 2025revenue guidanceFY2025$900.00M – $950.00MReaffirmed
Feb 26, 2025revenueFY2025$900.00M – $950.00MNew
Oct 30, 2024revenue guidanceFY2024$675.00M – $700.00MRaised
Jul 29, 2024revenueFY2024$640.00M – $670.00MRaised
May 1, 2024revenue guidanceFY2024$620.00M – $650.00MRaised
Feb 15, 2024revenueFY2024$600.00M – $630.00MNew
Nov 1, 2023revenueFY2023$470.00M – $480.00MRaised
Aug 2, 2023revenue guidanceFY2023$455.00M – $470.00MRaised
May 3, 2023revenueFY2023$435.00M – $455.00MRaised
Feb 28, 2023revenueFY2023$430.00M – $450.00MNew
Nov 3, 2022revenue guidanceFY2022$400.00M – $410.00MLowered
Aug 3, 2022revenueFY2022$400.00M – $430.00MReaffirmed
May 5, 2022revenueFY2022$400.00M – $430.00MReaffirmed
Feb 15, 2022revenueFY2022$400.00M – $430.00MNew
Nov 3, 2021revenue guidanceFY2021$365.00M – $375.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Corcept Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Corcept Announces Planned Leadership Transition
    Update
  2. Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
    Results
  3. Corcept Resubmits New Drug Application for Relacorilant
    News
  4. Corcept Therapeutics Announces First Quarter Financial Results
    Results
  5. FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli ™ (relacorilant)
    News
  6. Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
    Results
  7. Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals
    News
  8. Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in
    News
  9. Corcept Receives Complete Response Letter for Relacorilant
    News
  10. Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
    Results
  11. FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant
    News
  12. Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
    Results
  13. Corcept Submits New Drug Application for Relacorilant
    News
  14. CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
    Results
  15. PRIMARY ENDPOINT MET IN CORCEPT’S PIVOTAL PHASE 3 ROSELLA TRIAL OF
    News